Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Please always quote using this URN: urn:nbn:de:bvb:20-opus-249773
  • Background: With the availability of T-cell-directed therapy and next-generation compounds of established classes of drugs, the treatment of relapsed/refractory (r/r) myeloma is getting more complex. However, treatment options in practice are limited by availability, approval, and patient comorbidity. The aim of this article is to provide a practical approach toward the choice of treatment for r/r myeloma patients. Summary: Regarding market authorization and current guidelines, at least in Germany, most patients nowadays will have received aBackground: With the availability of T-cell-directed therapy and next-generation compounds of established classes of drugs, the treatment of relapsed/refractory (r/r) myeloma is getting more complex. However, treatment options in practice are limited by availability, approval, and patient comorbidity. The aim of this article is to provide a practical approach toward the choice of treatment for r/r myeloma patients. Summary: Regarding market authorization and current guidelines, at least in Germany, most patients nowadays will have received a doublet or triplet combination as first-line therapy containing a proteasome inhibitor and an immunomodulatory drug, mostly lenalidomide. We focus on the treatment options for patients that are ineligible for (another) stem cell transplantation. We will review treatment options for relapse after first- or second-line therapy and beyond third-line. Key Messages: There is promising data supporting the efficacy and safety of triplet combinations containing anti-CD38-monoclonal antibodies (anti-CD38 mAbs) at first or second relapse in combination with next-generation compounds. For the treatment beyond third-line, comparative studies are scarce but some promising compounds are available via conditional authorization, and there is more to come in the future. We will present some early phase trials featuring promising results.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Linda Heimberg, Stefan Knop
URN:urn:nbn:de:bvb:20-opus-249773
Document Type:Journal article
Faculties:Medizinische Fakultät / Medizinische Klinik und Poliklinik II
Language:English
Parent Title (English):Oncology Research and Treatment
ISSN:2296-5270
ISSN:2296-5262
Year of Completion:2021
Volume:44
Issue:12
Pagenumber:682-689
Source:Oncology Research and Treatment 2021;44,12:682–689. https://doi.org/10.1159/000520364
DOI:https://doi.org/10.1159/000520364
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/34794148
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:lenalidomide-refractory patients; myeloma
Release Date:2021/12/09
Date of first Publication:2021/11/18
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International